cti Logo Making Cancer More Treatable
Media / Press Kits /
 
Media Photo
XYOTAX
Pixantrone
 

Pixantrone

Pixantrone is an investigational drug that is designed to improve the activity and safety of the anthracycline family of anticancer agents. Pixantrone is currently in clinical development to treat non-Hodgkin's lymphoma (NHL).

Resources
• Pixantrone Fact Sheet (360k PDF)
• Press releases (searchable by key words)
• Pixantrone references (32k PDF)
• Pixantrone information on this web site
• Glossary of terms used on this site

Presentations at Industry Meetings
• Recent pixantrone  presentations are highlighted on our Investor Updates page and include:
  Bullet American Society of Hematology (ASH) Annual Meeting, December 2006
  Bullet American Society of Clinical Oncology (ASCO) Annual Meeting, June 2006
• Calendar of upcoming events

Contact CTI
For media inquiries:
Dan Eramian, T (206) 272-4343
Susan Callahan, T (206) 272-4472
(800) 215-CELL (US)
F (206) 272-4010
Media@ctiseattle.com

back to topback to top


Posted Feb. 2, 2007

Copyright © 2004-2007 Cell Therapeutics, Inc., Seattle, WA, USA. All rights reserved. "Making cancer more treatable" is a registered mark of CTI.